REHOVOT, Israel, April 07, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced an amendment to the GLASSIA® [Alpha ...
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces a significantly improved infusion rate for Glassia (Alpha1-Proteinase Inhibitor -Human); this ...
Switzerland is the first European country to approve Glassia®, which received U.S. FDA approval in 2010 Glassia will be commercialized by IDEOGEN AG in Switzerland and the therapy is expected to be ...
Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the second extension to supply Glassia® to Baxter in its strategic agreement ...
Glassia bottle Shire and Kamada announced that the Food and Drug Administration (FDA) has approved Glassia (alpha-1 proteinase inhibitor [human]) as the first treatment for adults with emphysema due ...
REHOVOT, Israel, April 07, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced an amendment to the GLASSIA® [Alpha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback